Literature DB >> 9177663

Competence thresholds for the use of inhalers in people with dementia.

S C Allen1.   

Abstract

METHODS: the ability to learn three inhaler techniques of increasing levels of complexity was studied in 50 normal and demented inhaler-naive elderly people (mean age 81 years) with stable 10-point mini-mental test scores (MTS). There were 10 subjects in each of the following groups: MTS 8-10 (non-demented), MTS 7 (borderline), MTS 6 (mild dementia), MTS 5 and MTS 4 (2 moderate dementia groups). The techniques were taught on one day and reassessed on the following day on consecutive days in ascending order of complexity.
RESULTS: those with an MTS of 4 were unable to learn any of the techniques, while all the non-demented people could learn all three techniques. For the five-stage technique (standard metered dose inhaler) the 0% threshold (i.e. when none of the subjects was able to learn) was MTS 6, the 50% threshold (at least half but not all could learn) MTS 7 and the 100% threshold (all could learn) MTS 8. For the four-stage technique (inhaler with large spacer) the 0% threshold was MTS 5, the 50% threshold MTS 6 and the 100% threshold MTS 8. For the three-stage technique (inspiration-triggered inhaler) the 0% threshold was MTS 4, the 50% threshold MTS 5 and the 100% threshold MTS 7.
CONCLUSIONS: MTS can be used to determine the likelihood of a mild or moderately demented patient being able to learn a multiple-stage inhaler technique.

Entities:  

Mesh:

Year:  1997        PMID: 9177663     DOI: 10.1093/ageing/26.2.83

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  21 in total

Review 1.  Overcoming gaps in the management of asthma in older patients: new insights.

Authors:  Pranoy Barua; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Aerosol therapy for obstructive lung diseases: device selection and practice management issues.

Authors:  Michael W Sims
Journal:  Chest       Date:  2011-09       Impact factor: 9.410

Review 3.  Optimizing Drug Therapies in Patients with COPD in the US Nursing Home Setting.

Authors:  Roy A Pleasants; Peter A Radlowski; H Edward Davidson
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

4.  Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial.

Authors:  P Diggory; C Fernandez; A Humphrey; V Jones; M Murphy
Journal:  BMJ       Date:  2001-03-10

Review 5.  Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids?

Authors:  Andrea P Rossi; Erika Zanardi; Mauro Zamboni; Andrea Rossi
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

6.  From Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines to current clinical practice : an overview of the pharmacological therapy of stable chronic obstructive pulmonary disorder.

Authors:  Raffaele Antonelli Incalzi; Andrea Corsonello; Claudio Pedone; Giulio Masotti; Vincenzo Bellia; Vittorio Grassi; Franco Rengo
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

7.  Ability to learn inhaler technique in relation to cognitive scores and tests of praxis in old age.

Authors:  S C Allen; S Ragab
Journal:  Postgrad Med J       Date:  2002-01       Impact factor: 2.401

8.  Caring for the older person with chronic obstructive pulmonary disease.

Authors:  Terri R Fried; Carlos A Vaz Fragoso; Michael W Rabow
Journal:  JAMA       Date:  2012-09-26       Impact factor: 56.272

9.  Erratum to: Safety Considerations of Inhaled Corticosteroids in the Elderly.

Authors:  Salvatore Battaglia; Irene Cardillo; Federico Lavorini; Mario Spatafora; Nicola Scichilone
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

Review 10.  Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

Authors:  Christopher M Blanchette; Nicholas J Gross; Pablo Altman
Journal:  Am Health Drug Benefits       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.